The 3 of them feel like this unique mix of people which bring a certain combination of exceptional traits to the table. A unique coincidence that seems to elevate the Precision molecule further and furhter... generation by generation. Hold on to this one folks #AVCT
Generic Grok valuation on #avct Precision-platform in case good efficacy published. My gutfeeling sits at 5Bio USD as base as well:
**Revised valuation summary (progressive steps)**
1. **Base platform**
Phase 1a biopsy data showing high tumor payload delivery + limited toxicity, two single-warhead assets, broad solid-tumor targeting potential (including HR-positive breast cancer, cervical cancer, and gastric cancer).
Rough enterprise value: **$1–2.5B**.
2. **+ Strong Phase 1 efficacy signals**
Disease control + many complete responses in pre-treated patients with HR-positive breast cancer, cervical cancer, gastric cancer, pancreatic cancer, and colorectal cancer.
Rough enterprise value: **$3.5–9B+**.
3. **+ Finalized IND for dual-warhead next-generation version on the same technology**
Rough enterprise value: **$5–12B+**.
These are order-of-magnitude ranges for a private (or early public) company based on deal comps, platform optionality, and typical re-rating on early clinical signals. Actual value would depend on response rates, durability, patient numbers, safety, cash position, and market conditions.
#cluand Vanaken is een goede voetballer maar een kleine mens...
Dus verkiezingen die door "links" gewonnen worden zijn verkiezingen die de democratie terugbrengen?! Heb ik dat goed gehoord? #deochtend
37
For all you 5-6 year #avct holders out there... the turnaround is nigh.
As if, the more the tumor tries to protect itself, the more it weakens its defenses... #avct seems to really have found its achilles heel. Happy to be corrected.
Did CC clearly mention that they already HAVE biopsies? I know they will have biopsies soon enough. But all the statements made, would be extra meaningful if indeed they are done already having biopsies at hand #avct
As the data seems to get better and better, the urge to postpone a deal becomes greater and greater... #avct is datamaxing ;-)
35
1,759
In between the lines, it sounded like AVA6103 can solve nearly everything... and AVA6207, that one will hopefully tackle the impossible ones... #avct
31
1,653
The tumor-pk will tell you what efficacy one can expect. So by the end of this year or very very early next year, for me it'll be a wrap. #AVCT
I think we all got a little bit too used to the fact that we are likely sitting on top of what could be called "the holy grail" of oncology. Stay seated! #avct
I suspect the AVA6103 trial is already saving lives of lost causes. #avct
16
1,321
Correct me if I am wrong: assuming potential partners under NDA get insights of biopsy and scan results as they come, those potential partners will have knowledge of efficacy already in the coming months. Being a potential partner, as soon as I get that info, I'd want to be the first one to pull the trigger. Waiting for official read-out in H1-2027 would simply be too risky. #avct
75



